Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:45 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
NCT04882163 · Celgene · PHASE1/PHASE2 · withdrawn · last registry update 2021-10-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business objectives have changed” | – | Registry record, Celgene |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CRBN within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-09-28Phase 3 first posted: PETHEMA Foundation, Bortezomib + Isatuximab (NCT05558319)
- 2022-08-29Phase 3 first posted: Celgene, mezigdomide + Pomalidomide (NCT05519085)
- 2022-08-01Also stopped (terminated): Criterium, Inc., Carfilzomib + Pomalidomide (NCT01464034)
- 2022-07-27Results posted on the registry: Oncopeptides AB, Melflufen + Pomalidomide (NCT03151811)
- 2022-07-13Phase 3 first posted: Janssen Research & Development, LLC, Talquetamab + Daratumumab (NCT05455320)
- 2022-06-29Phase 3 first posted: Janssen Research & Development, LLC, Daratumumab + Carfilzomib (NCT05438043)
- 2022-06-15Also stopped (withdrawn): Academic and Community Cancer Research United, Daratumumab + Dexamethasone (NCT03841565)
- 2022-06-06Phase 3 first posted: Sanofi, Isatuximab IV + Isatuximab SC (NCT05405166)
- 2022-05-23Results posted on the registry: Mayo Clinic, Dexamethasone + Ixazomib Citrate (NCT02547662)
- 2022-05-19Results posted on the registry: Mayo Clinic, Dexamethasone + Ixazomib Citrate (NCT03202628)
- 2022-05-11Results posted on the registry: Stichting European Myeloma Network, Daratumumab + Pomalidomide (NCT03180736)
- 2022-05-03Also stopped (withdrawn): Takeda, Ixazomib + Pomalidomide (NCT05183139)
- 2022-03-31Also stopped (terminated): Oncotherapeutics, Elotuzumab + Pomalidomide (NCT03104270)
- 2022-02-17Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Ipilimumab (NCT01592370)
- 2022-02-11Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Pomalidomide + Dexamethasone (NCT05236621)
- 2022-02-01Results posted on the registry: Oncopeptides AB, Melphalan flufenamide (Melflufen) + Dexamethasone (NCT02963493)
- 2022-01-10Results posted on the registry: Celgene, Pomalidomide + Dexamethasone (NCT01712789)
- 2021-10-28Results posted on the registry: MorphoSys AG, MOR03087 phase 1 dose escalation + MOR03087 (NCT01421186)
- 2021-10-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Ixazomib + Pomalidomide (NCT03170882)
- 2021-10-19Phase 3 first posted: Janssen Research & Development, LLC, Daratumumab + Pomalidomide (NCT05083169)
- 2021-10-08Also stopped (terminated): Merck Sharp & Dohme LLC, Pembrolizumab + Pomalidomide (NCT02576977)
- 2021-09-16Results posted on the registry: City of Hope Medical Center, ixazomib citrate + dexamethasone (NCT02119468)
- 2021-08-31Phase 3 first posted: European Myeloma Network B.V., Selinexor + Elotuzumab (NCT05028348)
- 2021-08-25Phase 3 first posted: Pfizer, Elranatamab + Daratumumab (NCT05020236)
- 2021-08-23Also stopped (withdrawn): Natalie Callendar, Elotuzumab + Pomalidomide (NCT04584307)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision